Squarepoint
NGNE icon

Squarepoint’s Neurogene NGNE Stock Holding History

Squarepoint’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,489
Closed -$669K – 4716
2025
Q4 		$669K Buy
+32,489
New +$809K ﹤0.01% 2961
2025
Q1 		– Sell
-17,431
Closed -$398K – 5142
2024
Q4 		$398K Buy
17,431
+12,451
+250% +$463K ﹤0.01% 3930
2024
Q3 		$209K Buy
+4,980
New +$193K ﹤0.01% 3659
2021
Q1 		– Sell
-839
Closed -$237K – 3453
2020
Q4 		$237K Buy
839
+111
+15% +$27.1K ﹤0.01% 2391
2020
Q3 		$175K Buy
+728
New +$176K ﹤0.01% 2142
2019
Q3 		– Sell
-748
Closed -$35K – 2567
2019
Q2 		$35K Buy
+748
New +$38.5K ﹤0.01% 2298
2018
Q4 		– Sell
-1,060
Closed -$62K – 2142
2018
Q3 		$62K Sell
1,060
-1,158
-52% -$68.3K ﹤0.01% 1914
2018
Q2 		$118K Buy
2,218
+858
+63% +$224K ﹤0.01% 1626
2018
Q1 		$383K Buy
+1,360
New +$376K 0.01% 1198

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Squarepoint's NGNE Position: Q1 2026 in Review

Squarepoint sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 32,489 shares — an estimated $669K sold.

Squarepoint first reported a position in NGNE in Q1 2018 and held it in 9 quarters. The position peaked at $669K in Q4 2025. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Squarepoint reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 32,489 Neurogene shares in Q1 2026, an estimated $669K.
  • Squarepoint first reported a position in Neurogene in Q1 2018 and held it in 9 quarters.
  • Squarepoint's Neurogene position peaked at $669K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.